The authors showed that loss of ARID1B in ARID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation in both cancer cells and primary cells, thus acting as a synthetic lethal and opening new therapeutic opportunities. This evidence concerns the gene ARID1A and cancer.